With low efficacy and high toxicity accounting for 70% of Phase II and 87% of Phase III clinical attrition, improving predictive in vitro models has never been such a high priority. The 3rd Annual Developing More Predictive In Vitro Models Summit will showcase a range of new platforms and technologies that address this issue directly. High potential compounds will be prioritized, toxicity mitigated and clinical strategy directed by development and validation of this new breed of in vitro models. During research for this meeting, your peers asked for an agenda packed full with the latest improvements in established in vitro models and exciting developments in 3D culture, stem cell and lab-on-a-chip technologies. With candid discussion on these issues guaranteed from senior level figures at the FDA, Novartis, Roche, Abbott, Pfizer and many more, this meeting will provide the most valuable strategic learning experience of the year.